The Von Hippel-Lindau Tumor Suppressor Gene and Kidney Cancer
- 15 September 2004
- journal article
- review article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 10 (18), 6290S-6295S
- https://doi.org/10.1158/1078-0432.ccr-sup-040025
Abstract
The von Hippel-Lindau tumor suppressor gene (VHL), which resides on chromosome 3p25, is mutated or silenced in >50% of sporadic clear cell renal cell carcinomas. Germ-line VHL mutations give rise to VHL disease, which is characterized by an increased risk of blood vessel tumors (hemangioblastomas) and renal cell carcinomas. In this setting, VHL inactivation gives rise to premalignant renal cysts. Additional genetic alterations are presumably required for conversion of these cysts to renal cell carcinomas. Restoration of VHL function in VHL−/− renal cell carcinomas is sufficient to inhibit tumorigenesis in vivo. On the basis of these and other data, VHL appears to be a critical gatekeeper with respect to the development of renal cell carcinoma. The VHL gene product, pVHL, is the substrate recognition module of an E3 ubiquitin ligase that targets the hypoxia-inducible factor (HIF) for destruction in the presence of oxygen. Hypoxic cells, or cells lacking pVHL, accumulate high levels of HIF, which activates the transcription of a variety of genes, including vascular endothelial growth factor, platelet-derived growth factor B, and transforming growth factor α. We have demonstrated that inhibition of HIF is necessary and sufficient for tumor suppression by pVHL in renal cell carcinoma nude mouse xenograft assays. This provides a rationale for treating VHL−/− renal cell carcinoma with inhibitors of HIF or its downstream targets. Genotype-phenotype correlations in VHL disease suggest, however, that pVHL has targets in addition to HIF. Elucidating these targets should provide a more complete picture of how pVHL suppresses tumor growth.Keywords
This publication has 70 references indexed in Scilit:
- Inhibition of HIF2α Is Sufficient to Suppress pVHL-Defective Tumor GrowthPLoS Biology, 2003
- Oxygen-Dependent Ubiquitination and Degradation of Hypoxia-Inducible Factor Requires Nuclear-Cytoplasmic Trafficking of the von Hippel-Lindau Tumor Suppressor ProteinMolecular and Cellular Biology, 2002
- Identification of a deubiquitinating enzyme subfamily as substrates of the von Hippel–Lindau tumor suppressorBiochemical and Biophysical Research Communications, 2002
- Role of transforming growth factor-alpha in von Hippel- Lindau (VHL)-/- clear cell renal carcinoma cell proliferation: A possible mechanism coupling VHL tumor suppressor inactivation and tumorigenesisProceedings of the National Academy of Sciences of the United States of America, 2001
- Comparative Sequence Analysis of the VHL Tumor Suppressor GeneGenomics, 2000
- Treatment of polycystic kidney disease with a novel tyrosine kinase inhibitorKidney International, 2000
- An Important von Hippel-Lindau Tumor Suppressor Domain Mediates Sp1-Binding and Self-AssociationBiochemical and Biophysical Research Communications, 1999
- Direct Interaction of the β-Domain of VHL Tumor Suppressor Protein with the Regulatory Domain of Atypical PKC IsotypesBiochemical and Biophysical Research Communications, 1999
- Alternate choice of initiation codon produces a biologically active product of the von Hippel Lindau gene with tumor suppressor activityOncogene, 1999
- Multiple Intestinal Neoplasia Caused by a Mutation in the Murine Homolog of the APC GeneScience, 1992